⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23409341 | 1.00 | — | — | |
| SCHEMBL27053769 | 0.81 | ENPP3 (0.30) | — | |
| SCHEMBL25376794 | 0.81 | — | — | |
| SCHEMBL25336321 | 0.78 | MAT2A (0.33) | — | |
| SCHEMBL24711969 | 0.78 | EPRS1 (0.38) | — | |
| SCHEMBL24870471 | 0.78 | — | — | |
| SCHEMBL24917739 | 0.78 | — | — | |
| SCHEMBL19096220 | 0.76 | — | — | |
| SCHEMBL25336104 | 0.76 | MBOAT4 (0.34) | — | |
| SCHEMBL28501805 | 0.74 | ALDH1A1 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731309-A1 | KRAS PROTEOLYSIS TARGETING CHIMERAS | Paq Therapeutics Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4598921-A1 | MACROCYCLIC KRAS INHIBITORS AND METHODS OF USE | Amgen Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-4584276-A1 | KRAS G12D INHIBITORS | Bristol-Myers Squibb Company (US) | 2025-07-16 | — | — | EP | disclosed |
| EP-4573089-A2 | KRAS INHIBITORS | Bristol-Myers Squibb Company (US) | 2025-06-25 | — | — | EP | disclosed |
| US-20250179077-A1 | QUINAZOLINE COMPOUNDS AND USES THEREOF AS INHIBITORS OF MUTANT KRAS PROTEINS | AMGEN INC. (US) | 2025-06-05 | — | — | US | disclosed |
| CN-120092011-A | KRAS G12D inhibitors | 百时美施贵宝公司 | 2025-06-03 | — | — | CN | disclosed |
| EP-4551574-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BeiGene, Ltd. (KY) | 2025-05-14 | — | — | EP | disclosed |
| CN-119998275-A | KRAS inhibitors | 百时美施贵宝公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-119790059-A | Heterocyclic compounds as KRAS inhibitors, their preparation and therapeutic use | 上海科州药物股份有限公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-119677726-A | KRAS inhibitors | 百时美施贵宝公司 | 2025-03-21 | — | — | CN | disclosed |
| WO-2022258974-A1 | QUINAZOLINE DERIVATIVES USEFUL AS RAS INHIBITIORS | REDX PHARMA PLC (GB) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022247760-A1 | HETEROCYCLIC COMPOUNDS AS KRAS INHIBITOR, AND PREPARATION THEREFOR AND USE THEREOF IN TREATMENT | 上海科州药物研发有限公司 | 2022-12-01 | — | — | WO | disclosed |
| CN-115385938-A | Benzopyrimidine compounds, preparation method thereof and application thereof in medicines | 江苏恒瑞医药股份有限公司 | 2022-11-25 | — | — | CN | disclosed |
| CN-115368381-A | Preparation and application of heterocyclic inhibitor | 药雅科技(上海)有限公司 | 2022-11-22 | — | — | CN | disclosed |
| CN-115304603-A | Preparation and application of quinazoline inhibitor | 药雅科技(上海)有限公司 | 2022-11-08 | — | — | CN | disclosed |
| WO-2022232331-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2022-11-03 | — | — | WO | disclosed |
| WO-2022228568-A1 | PYRIDINO- OR PYRIMIDO-CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 劲方医药科技(上海)有限公司 | 2022-11-03 | — | — | WO | disclosed |
| WO-2022192794-A1 | KRAS G12D INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-09-15 | — | — | WO | disclosed |
| CN-115003677-A | Compounds having inhibitory activity against KRAS G12D mutation | 大鹏药品工业株式会社 | 2022-09-02 | — | — | CN | disclosed |
| WO-2022098625-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-05-12 | — | — | WO | disclosed |